“ The trial met the primary efficacy endpoint: the proportion of patients with ≥0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the one-week treatment period (p?0.01).”
Correct 0.0032 is the best p-value , or close to the best you can get basically the gold standard. Also BLA filing is imminent, and CYDY is a buy just based on that alone.